Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

cAMPfield Therapeutics Launches with $180M Series A to Advance Prifemilast PDE4 Inhibitor for IBD

Fineline Cube Jul 7, 2026
Company Deals

BriSTAR Immunotech Secures $28M Series C to Advance STAR-T Platform and In Vivo Technology

Fineline Cube Jul 7, 2026
Company Deals

Formosa Pharmaceuticals, Samil Pharma Expand Partnership with APP13007 Vietnam Licensing Deal

Fineline Cube Jul 7, 2026
Company Deals

Carephar Pharmaceutical, Silk Road Medical Forge Central Asia Deal for Keverprazan P-CAB Innovation

Fineline Cube Jul 7, 2026
Company Deals

Astex Pharmaceuticals, Genentech Forge $515M Breast Cancer Small Molecule Drug Collaboration

Fineline Cube Jul 7, 2026
Policy / Regulatory

Guangdong Launches “Spring Rain Action” to Accelerate Medical Device Innovation Transformation with 900+ Clinical Achievements Target

Fineline Cube Jul 7, 2026
Company Drug

Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic

Fineline Cube Jul 6, 2026
Company Drug

Shaanxi Micot Enrolls First Patient in Phase Ib/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment

Fineline Cube Jul 6, 2026
Company Drug

AstraZeneca and Daiichi Sankyo’s Dato-DXd Misses Overall Survival Endpoint but Shows Promise in NSCLC Subgroup

Fineline Cube Sep 10, 2024

AstraZeneca (NASDAQ: AZN) and its co-development partner, Japan’s Daiichi Sankyo, have released data from the...

Company Deals

Candel Therapeutics Acquires Bispecific Antibodies and Secures $370 Million in Financing for Autoimmune Drug Development

Fineline Cube Sep 10, 2024

Candel Therapeutics, Inc. (CADL), a U.S.-based biopharmaceutical company, has announced the acquisition of two U.S....

Company Drug

Vcanbio’s Stem Cell Therapy VUM02 Gets NMPA Approval for Systemic Sclerosis Clinical Trial

Fineline Cube Sep 10, 2024

Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645), a biotechnology company based in China,...

Company Deals

Insilico Medicine Partners with Inimmune Corporation to Utilize AI for Immunotherapy Innovation

Fineline Cube Sep 10, 2024

Insilico Medicine, a leading artificial intelligence-driven drug discovery company based in China, has announced a...

Policy / Regulatory

NHC Releases Updated List of Pediatric Drugs for Research and Development Incentives

Fineline Cube Sep 10, 2024

The National Health Commission (NHC) has issued a notification regarding the fifth batch of pediatric...

Company Drug

Innovent Biologics’ Dupert Demonstrates Positive Results in Phase II NSCLC Trial

Fineline Cube Sep 10, 2024

Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...

Drug Policy / Regulatory

China’s CDE Issues Draft Guidelines for Biosimilar Pharmaceutical Similarity Research

Fineline Cube Sep 10, 2024

The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has released...

Company Deals R&D

Tigermed Partners with Purpose Africa to Boost Clinical Research and Healthcare Cooperation

Fineline Cube Sep 9, 2024

Tigermed (SHE: 300347), a leading Contract Research Organization (CRO) in China, has entered into a...

Policy / Regulatory

China’s 2024 Negative List Eases Restrictions on Foreign Investment in TCM and Biotechnology

Fineline Cube Sep 9, 2024

The National Development and Reform Commission (NDRC) of China has announced the release of the...

Policy / Regulatory

China’s NMPA Proposes Inclusion of Cochlear Implants in Volume-Based Procurement Plans

Fineline Cube Sep 9, 2024

The National Medical Products Administration (NMPA) has disclosed plans to expand the scope of its...

Company Deals Medical Device

Edwards Lifesciences Sells ICU Business to BD in $4.2 Billion Deal, Announces Layoffs

Fineline Cube Sep 9, 2024

Edwards Lifesciences, a leading U.S. medical device company, has reportedly reached an agreement to sell...

Company Drug

Zelgen Biopharma’s ZG006 Shows Promising Anti-Tumor Efficacy in Phase I/II SCLC Study

Fineline Cube Sep 9, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...

Policy / Regulatory

China’s NHSA Proposes New Guidelines to Enhance Oversight of Medical Insurance Funds

Fineline Cube Sep 9, 2024

The National Healthcare Security Administration (NHSA) has unveiled a draft of the “Guiding Opinions on...

Company Deals

Caprico Biotechnologies and Mindray Medical Form Comprehensive Flow Testing Partnership

Fineline Cube Sep 9, 2024

Caprico Biotechnologies, Inc., a Chinese biotechnology company, has entered into a comprehensive partnership with Mindray...

Policy / Regulatory

China Opens Doors to Foreign Biotech and Wholly-Owned Hospitals in Healthcare Sector Expansion

Fineline Cube Sep 9, 2024

China’s Ministry of Commerce, National Health Commission, and National Medical Products Administration (NMPA) have jointly...

Company

Connect Biopharma Shifts Focus to US, Plans Further Reduction in China Workforce

Fineline Cube Sep 9, 2024

Connect Biopharma Holdings Ltd (NASDAQ: CNTB), a Sino-US biotechnology company that initially operated in Suzhou...

Policy / Regulatory

Guangzhou Health Commission Unveils Ten Measures to Boost Innovative Pharma and Medical Device Development

Fineline Cube Sep 9, 2024

On September 5, 2024, the Guangzhou Health Commission issued the “Guangzhou Health Commission’s Ten Measures...

Company Drug

Merck and Daiichi Sankyo’s Ifinatamab Deruxtecan Shows Promising Results in Phase II ES-SCLC Trial

Fineline Cube Sep 9, 2024

Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK), a leading U.S. pharmaceutical company, and its...

Company Policy / Regulatory

Biosecure Act Faces Opposition from Senior House Democrat Jim McGovern

Fineline Cube Sep 9, 2024

The trajectory of the US Biosecure Act through the House of Representatives encountered unexpected turbulence...

Company Drug Policy / Regulatory

China’s CDE Releases 86th Batch of Reference Preparations for Generic Drug Evaluation

Fineline Cube Sep 9, 2024

China’s Center for Drug Evaluation (CDE) has unveiled its 86th roster of reference preparations for...

Posts pagination

1 … 325 326 327 … 691

Recent updates

  • cAMPfield Therapeutics Launches with $180M Series A to Advance Prifemilast PDE4 Inhibitor for IBD
  • BriSTAR Immunotech Secures $28M Series C to Advance STAR-T Platform and In Vivo Technology
  • Formosa Pharmaceuticals, Samil Pharma Expand Partnership with APP13007 Vietnam Licensing Deal
  • Carephar Pharmaceutical, Silk Road Medical Forge Central Asia Deal for Keverprazan P-CAB Innovation
  • Guangdong Launches “Spring Rain Action” to Accelerate Medical Device Innovation Transformation with 900+ Clinical Achievements Target
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

cAMPfield Therapeutics Launches with $180M Series A to Advance Prifemilast PDE4 Inhibitor for IBD

Company Deals

BriSTAR Immunotech Secures $28M Series C to Advance STAR-T Platform and In Vivo Technology

Company Deals

Formosa Pharmaceuticals, Samil Pharma Expand Partnership with APP13007 Vietnam Licensing Deal

Company Deals

Carephar Pharmaceutical, Silk Road Medical Forge Central Asia Deal for Keverprazan P-CAB Innovation

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.